BCL2L1 and neoplasm: We wanted to know if this clinical agent could be used in conjunction with TAN-targeting A-1331852, reasoning that (i) it could act against A-1331852 by increasing neutrophil production and their infiltration into tumors, augmenting the total pool of TANs, or (ii) it could potentiate the effects of A-1331852, by providing younger neutrophils while Bcl-xL blockade selectively removes older TANs, together shifting the balance toward young (and possibly anti-tumor) TANs (Fig. 5A).